Klinik Araştırma

The Role of Irisin, Copper and Zinc Levels on Insulin Resistance in Polycystic Ovary Syndrome

Cilt: 1 Sayı: 1 22 Eylül 2020
Mustafa Bayraktar *, Ali Sami Gürbüz , Bahadır Öztürk
PDF İndir
EN

The Role of Irisin, Copper and Zinc Levels on Insulin Resistance in Polycystic Ovary Syndrome

Abstract

Background: Polycystic Ovary Syndrome (PCOS) is the most common endocrine disorder in women of reproductive age. Irisin is defined as a myocin released from skeletal muscle that protects individuals from metabolic diseases when exercised regularly. Zinc is thought to play an active role in the pathophysiology of PCOS in relation to insulin resistance. Copper has been stated to contribute to oxidative stress and insulin resistance in PCOS patients. The aim of this study was to evaluate the relationship between serum irisin, copper and zinc levels and insulin resistance in PCOS patients and control cases. Methods: Our study consists of a patient group of 45 individuals diagnosed with PCOS and a healthy control group of 45 individuals. 2003 Rotterdam diagnostic criteria were used for the diagnosis of PCOS. Serum copper, zinc and irisin levels were measured and evaluated with regard to Body Mass Index and insulin resistance. Results: Serum zinc and copper levels were found to be higher in PCOS patients compared to controls (p<0.05), however no statistically significant differences were found between the groups with regard to HOMA-IR and serum irisin levels. Conclusions: It was evaluated that the data obtained from the patient group in this study may have been effected due to patients’ use of some medications like metformin, multivitamin supplements and oral contraceptives.

Keywords

PCOS , Irisin , Insulin Resistance , Copper , Zinc

Kaynakça

  1. 1.Di Pietro M, Pascuali N, Parborell F, Abramovich D. Ovarian angiogenesis in polycystic ovary syndrome. Reproduction. 2018;155(5):R199-R209.
  2. 2. Speroff L, Fritz MA. Clinical gynecologic endocrinology and infertility. 7th ed. Philadelphia, USA: lippincott Williams & wilkins; 2005.
  3. 3. Shannon M, Wang Y. Polycystic ovary syndrome: a common but often unrecognized condition. Journal of midwifery & women’s health. 2012;57(3):221-30.
  4. 4. Baysal B. Polikistik over sendromu ve hirsutizm. İÜ Cerrahpaşa Tıp Fakültesi Sürekli Tıp Eğitimi Etkinlikleri Sempozyum Dizisi2008. p. 99-107.
  5. 5. Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome (PCOS): the hypothesis of PCOS as functional ovarian hyperandrogenism revisited. Endocrine reviews. 2016;37(5):467-520.
  6. 6. Evliyaoglu O. Polycystic ovary syndrome and hirsutism/Polikistik over sendromu ve hirsutizm. J Turkish Pediatrics Archive. 2011:S97-S.
  7. 7. Vrbíková J, Bendlová B, Hill M, Vanková M, Vondra K, Stárka L. Insulin sensitivity and β-cell function in women with polycystic ovary syndrome. J Diabetes Care. 2002;25(7):1217-22.
  8. 8. Kucur SK, Yüksel B, Seven A, Polat M, Keskin N, Aksoy AN. Farklı Dört Polikistik Over Sendromu Fenotipinin Klinik Ve Laboratuvar Değerlerinin Karşılaştırılması. J Mustafa Kemal Üniversitesi Tıp Dergisi. 2016;7(26).
  9. 9. Şahin SB, Sümer F, Sezgin H, Ayaz T, Şahin OZ, İlkkılıç K, et al. Polikistik over sendromlu hastalarda obezitenin klinik, metabolik ve hormonal özellikler üzerine etkisi. J Journal of Clinical Experimental Investigations. 2014;5(4):567-71.
  10. 10. Diamanti-Kandarakis E. Role of obesity and adiposity in polycystic ovary syndrome. J International journal of obesity. 2007;31(2):S8-S13.

Kaynak Göster

APA
Bayraktar, M., Gürbüz, A. S., & Öztürk, B. (2020). The Role of Irisin, Copper and Zinc Levels on Insulin Resistance in Polycystic Ovary Syndrome. Archives of Current Medical Research, 1(1), 12-18. https://doi.org/10.47482/acmr.2020.2